This site is intended for Healthcare professionals only.

Gilead announces USFDA Priority Review Designation for FDC of Bictegravir, Emtricitabine, Tenofovir Alafenamide to treat HIV

Gilead announces USFDA Priority Review Designation for FDC of Bictegravir, Emtricitabine, Tenofovir Alafenamide to treat HIV

FOSTER CITY, Calif: Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the company’s New Drug Application (NDA) for an investigational, fixed-dose combination of bictegravir (50mg) (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25mg) (FTC/TAF), a dual-NRTI backbone, for the treatment of HIV-1 infection.

Gilead filed the NDA for BIC/FTC/TAF with a Priority Review voucher on June 12, 2017, and FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of February 12, 2018.

The NDA is supported by data from four Phase 3 studies that evaluated the fixed-dose combination among treatment-naïve patients and among virologically suppressed patients. A marketing application for BIC/FTC/TAF is also under review in the European Union, and was validated by the European Medicines Agency (EMA) in July.

Bictegravir in combination with FTC/TAF as a single tablet regimen is an investigational treatment that has not been determined to be safe or efficacious and is not approved anywhere globally.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

Source: Press Release
0 comment(s) on Gilead announces USFDA Priority Review Designation for FDC of Bictegravir, Emtricitabine, Tenofovir Alafenamide to treat HIV

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted